Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Change in Receivables (2022 - 2025)

Historic Change in Receivables for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Q3 2025 value amounting to $30000.0.

  • Amylyx Pharmaceuticals' Change in Receivables rose 10127.06% to $30000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.6 million, marking a year-over-year increase of 9421.48%. This contributed to the annual value of -$39.6 million for FY2024, which is 26004.69% down from last year.
  • As of Q3 2025, Amylyx Pharmaceuticals' Change in Receivables stood at $30000.0, which was up 10127.06% from -$198000.0 recorded in Q2 2025.
  • Amylyx Pharmaceuticals' 5-year Change in Receivables high stood at $15.9 million for Q2 2023, and its period low was -$19.7 million during Q1 2024.
  • Its 4-year average for Change in Receivables is -$333.33, with a median of -$172500.0 in 2025.
  • Per our database at Business Quant, Amylyx Pharmaceuticals' Change in Receivables plummeted by 97585.59% in 2024 and then skyrocketed by 10127.06% in 2025.
  • Amylyx Pharmaceuticals' Change in Receivables (Quarter) stood at $15.2 million in 2022, then decreased by 29.48% to $10.7 million in 2023, then tumbled by 111.99% to -$1.3 million in 2024, then surged by 102.34% to $30000.0 in 2025.
  • Its last three reported values are $30000.0 in Q3 2025, -$198000.0 for Q2 2025, and -$147000.0 during Q1 2025.